1.Recent advance in tailored treatment of gastric cancer.
Hei Cheul JEUNG ; Sun Young RHA
Korean Journal of Medicine 2009;77(1):1-8
Even the overall incidence is decreasing and the proportion of early gastric cancer is increasing from the national mass screening program, still gastric cancer is the major issue in Korea. Multimodality approach and the development of novel therapeutic agents enabled us to improve the survival rate of gastric cancer. However, the proper treatment strategy for the subgroups of patients is necessary, which is now categorized based on the clinicopathologic parameters. We need more in-depth information regarding the molecular biology of gastric cancer, and the development of novel targeted biological agents and the biomarkers for the future. Currently, the recent chemotherapeutic agents showed the improved response in advanced gastric cancer. Hence, the basic concept of adjuvant chemotherapy, palliative chemotherapy, neoadjuvant treatment with or without incorporation of radiotherapy become settle down with more evidences from several phase III trials. Especially, after understanding the difference between Asia and Western countries including biology, ethnic difference, operation technology, and the treatment approaches, the qualified, well-designed multinational clinical trials are on-going. Based on the current results, here, I describe the current status of gastric cancer treatment strategy.
Asia
;
Biological Agents
;
Biomarkers
;
Biology
;
Chemotherapy, Adjuvant
;
Humans
;
Incidence
;
Korea
;
Mass Screening
;
Molecular Biology
;
Neoadjuvant Therapy
;
Stomach Neoplasms
;
Survival Rate
2.Chemotherapy in Cancer Patients with Comorbidity.
Hei Cheul JEUNG ; Yong Wha MOON
Journal of the Korean Gastric Cancer Association 2004;4(2):59-74
This report attempts to explain the (i) implications of comorbidity for research and practice in the fieldo of oncology, (ii) the approach for dosing of anti-cancer drugs in the presence of comorbidity, as an example of its clinical application, and finally (iii) the dosing guidelines for the anticancer drugs clinically active in gastric cancer in the presence of renal or liver dysfunction. This has resulted from the idea of approaching comorbidity in a systematic way and of integrating it with oncologic decisions. Various methods have been used to assess comorbidity. However, significant work remains to be done to analyze how various diseases combine to influence the oncologic outcome. The main end-point explored so far has been mortality, but a largely open challenge remains to correlate comorbidity with treatment tolerance and functional and quality of life, as well as to integrate it in clinical decision-making. Cancer chemotherapy in comorbidity should be considered as an example of the need for dose optimization in individual patients, and it should be determined by considering the basic principles of the pharmacokinetics and the pharmacodynamics of the agents. This review analyzes the available data on the pharmacokinetics and the toxicities of anti-cancer agents in the comorbidity population.
Comorbidity*
;
Drug Therapy*
;
Humans
;
Liver Diseases
;
Mortality
;
Pharmacokinetics
;
Quality of Life
;
Stomach Neoplasms
3.Significant Gene Selection Using Integrated Microarray Data Set with Batch Effect.
Ki Yeol KIM ; Hyun Cheol CHUNG ; Hei Cheul JEUNG ; Ji Hye SHIN ; Tae Soo KIM ; Sun Young RHA
Genomics & Informatics 2006;4(3):110-117
In microarray technology, many diverse experimental features can cause biases including RNA sources, microarray production or different platforms, diverse sample processing and various experiment protocols. These systematic effects cause a substantial obstacle in the analysis of microarray data. When such data sets derived from different experimental processes were used, the analysis result was almost inconsistent and it is not reliable. Therefore, one of the most pressing challenges in the microarray field is how to combine data that comes from two different groups. As the novel trial to integrate two data sets with batch effect, we simply applied standardization to microarray data before the significant gene selection. In the gene selection step, we used new defined measure that considers the distance between a gene and an ideal gene as well as the between-slide and within-slide variations. Also we discussed the association of biological functions and different expression patterns in selected discriminative gene set. As a result, we could confirm that batch effect was minimized by standardization and the selected genes from the standardized data included various expression pattems and the significant biological functions.
Bias (Epidemiology)
;
Computational Biology
;
Dataset*
;
Genes, vif
;
RNA
4.Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction.
Semi PARK ; Sang Joon SHIN ; Joong Bae AHN ; Hei Cheul JEUNG ; Sun Young RHA ; Sang Kil LEE ; Hyun Cheol CHUNG
Yonsei Medical Journal 2009;50(2):296-299
Malignant obstruction develops frequently in advanced gastric cancer. Although it is primarily the gastric outlet that is obstructed, there are occasional reports of colonic obstruction. Treating intestinal obstruction usually requires emergency surgery or stent insertion. There are several kinds of complications with stent insertion, such as bowel perforation, stent migration, bleeding, abdominal pain and reobstruction. Nevertheless, endoscopic stent insertion could be a better treatment than emergency surgery in cases of malignant bowel obstruction in cancer patients with poor performance status. We report a case of advanced gastric cancer with carcinomatosis in which a recurrent colonic stent was inserted at the same site because of cancer growth into the stent. The patient maintained a good condition for chemotherapy, thus improving their chances for survival.
Aged
;
Female
;
Humans
;
Intestinal Obstruction/etiology/radiography/*surgery
;
Neoplasm Recurrence, Local
;
Prosthesis Implantation/*methods
;
*Stents
;
Stomach Neoplasms
5.Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors
Hei Cheul JEUNG ; Se Eung OH ; Jee Hung KIM
Journal of Rheumatic Diseases 2019;26(4):221-234
Recent studies on T cell immunology have been instrumental in developing therapies to overcome cancer immune escape, and immune checkpoint inhibitors have emerged as one of the most promising therapeutic tools in advanced cancer patients. Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that modulate the effects of immune checkpoints. These include cytotoxic T lymphocyte antigen 4 and programmed cell death protein 1, which are co-inhibitory signals responsible for immune suppression. Despite their clinical benefits, ICPIs behave as general immune activators, exerting to several toxic effects called immune-related adverse events attributed to organ-specific inflammation. Here, we review ICPI toxicities, highlighting the importance of their early identification and proper management.
Adrenal Cortex Hormones
;
Allergy and Immunology
;
Antibodies, Monoclonal
;
Cell Death
;
CTLA-4 Antigen
;
Humans
;
Inflammation
;
United Nations
6.A case of toxoplasmosis mimicking systemic recurrence in a patient treated with breast cancer.
Beom Kyung KIM ; Byoung Chul CHO ; Yong Won LEE ; Hyun Soo CHUNG ; Hei Cheul JEUNG ; Sun Yong RHA ; Hyun Cheol CHUNG
Korean Journal of Medicine 2006;71(1):108-113
Left cervical lymphadenopathy was found in a 48-year-old Korean female patient who had been treated for breast cancer 3 years ago. A presumative diagnosis was lymph nodal and lung metastasis of breast cancer during chest CT and neck CT. Core needle biopsy was undertaken. Pathological examination of lymph node revealed reactive hyperplasia consistent with toxoplasmosis, and toxoplasma Ig M antibody was also positive. Finally, she was diagnosed as toxoplasmosis, not metastasis of breast cancer. As she had no symptoms, no specific treatment was necessary. Follow up chest and neck CT scan after 5 months later showed resolved lung lesion, and size decrement of cervical lymph node. So, she has no evidence of recurrence and is now under clinical follow up. Recognition that toxoplasmosis can mimic metastasis is important in reaching the correct diagnosis and treatment.
Biopsy, Large-Core Needle
;
Breast Neoplasms*
;
Breast*
;
Diagnosis
;
Female
;
Follow-Up Studies
;
Humans
;
Hyperplasia
;
Lung
;
Lymph Nodes
;
Lymphatic Diseases
;
Middle Aged
;
Neck
;
Neoplasm Metastasis
;
Recurrence*
;
Thorax
;
Tomography, X-Ray Computed
;
Toxoplasma
;
Toxoplasmosis*
7.S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer.
Jong Yul JUNG ; Sun Young RHA ; Joong Bae AHN ; Woo Ick YANG ; Sung Hoon NOH ; Hyun Cheol CHUNG ; Hei Cheul JEUNG
The Korean Journal of Internal Medicine 2008;23(1):37-41
S-1, a novel oral fluoropyrimidine, is an effective therapeutic agent for gastric cancer. Herein, we report a case with locally advanced gastric cancer that achieved a curative resection after S-1 monotherapy as neoadjuvant treatment. A 68-year-old man was diagnosed with gastric cancer and massive lymphadenopathy involving the perigastric, celiac axis and splenic hilum. His clinical stage was cT3N2H0P0M0. Considering his relatively poor performance (ECOG 2, severe weight loss) and advanced age, we started the patient on S-1 monotherapy at a dose of 35 mg/m2 bid for 4 consecutive weeks followed by a 2-week rest. Follow-up study after 4 treatment cycles revealed disappearance of the lymphadenopathy of the perigastric and celiac axis with diminished extension of the stomach mass. The patient had a partial response (PR) with a 72% tumor reduction, according to the Response Evaluation Criteria in Solid Tumors (RECIST). His performance status was improved to an ECOG 1 and he gained 7 kg. A curative (R0) resection was achieved with a radical total gastrectomy and D2 dissection. The pathological stage was pT3N2M0, stage IIIB. In conclusion, S-1 neoadjuvant chemotherapy aided in the treatment of gastric cancer in this patient.
Adenocarcinoma/*drug therapy/pathology/surgery
;
Aged
;
Antimetabolites, Antineoplastic/administration & dosage/*therapeutic use
;
Drug Combinations
;
Gastrectomy
;
Humans
;
Male
;
*Neoadjuvant Therapy
;
Neoplasm Staging
;
Oxonic Acid/administration & dosage/*therapeutic use
;
Stomach Neoplasms/*drug therapy/pathology/surgery
;
Tegafur/administration & dosage/*therapeutic use
8.Leptomeningeal Carcinomatosis in Solid Tumors; Clinical Manifestation and Treatment.
Joon Oh PARK ; Hyun Joon SHIN ; Hyung Jong KIM ; Sang Wook LEE ; Hei Cheul JEUNG ; Seung Min KIM ; Nae Choon YOO ; Hyun Cheol CHUNG ; Joo Hang KIM ; Byung Soo KIM ; Jin Sik MIN ; Jae Kyung ROH
Journal of the Korean Cancer Association 2001;33(1):34-40
PURPOSE: Leptomeningeal carcinomatosis occurs in about 5% of patients with solid tumor and is being diagnosed with increasing frequency as patients live longer and as neuro-imaging studies improve. In general, the most commom cancers that involved the leptomeninges are breast cancer, lung cancer, and malignant melanoma. MATERIALS AND METHODS: We investigated 25 patients presented with multiple neurologic symptoms and signs who were diagnosed with leptomeningeal carcinomatosis at the Yonsei Cancer Center from January 1990 to December 1999. RESULTS: The primary disease of leptomeningeal carcinomatosis were stomach cancer (10 cases), breast cancer (7 cases), lung cancer (5 cases), unknown primary cancer (2 cases) and common bile duct cancer (1 case). All patients were presented with multiple neurologic symptoms and signs involving the central nervous system (CNS), cranial nerve or spinal nerves. Twenty-one of twenty- five patients were treated with intrathecal chemotherapy, radiotherapy, or combination therapy. Fourteen of them (66.7%) experienced improvement or stabilization of neurologic symptom and sign. The median survival was 122 days (10-2190). CONCLUSION: In conclusion, although early diagnosis and active treatment of leptomeningeal carcinomatosis may improve the quality of life in selected patients, the median survival was relatively short. Therefore, new diagnostic and therapeutic strategy for leptomeningeal carcinomatosis were needed.
Breast Neoplasms
;
Central Nervous System
;
Common Bile Duct
;
Cranial Nerves
;
Drug Therapy
;
Early Diagnosis
;
Humans
;
Lung Neoplasms
;
Melanoma
;
Meningeal Carcinomatosis*
;
Neurologic Manifestations
;
Quality of Life
;
Radiotherapy
;
Spinal Nerves
;
Stomach Neoplasms
9.Wernicke's Encephalopathy in Advanced Gastric Cancer.
Eun Suk JUNG ; Obin KWON ; Soo Hyun LEE ; Ki Byung LEE ; Joo Hoon KIM ; Sang Hyun YOON ; Gun Min KIM ; Hei Cheul JEUNG ; Sun Young RHA
Cancer Research and Treatment 2010;42(2):77-81
PURPOSE: With their prolonged survival and malnutrition, cancer patients, and especially gastrointestinal (GI) tract cancer patients, can develop Wernicke's encephalopathy (WE). The aim of this study is to remind physicians of the importance of WE and prompt management in patients with GI tract cancer. MATERIALS AND METHODS: This study is a retrospective review of 2 cases of WE in advanced gastric cancer (AGC) patients, and we review the literature for cases of GI tract cancer related to WE. RESULTS: A 48-year-old female with AGC presented dizziness and diplopia for 5 days and a 20 kg weight loss. Neurologic exam showed nystagmus and gaze disturbance. Her symptoms improved after daily parenteral injection of thiamine 100 mg for 17 days. A 58-year-old female with AGC presented with sudden disorientation, confusion and 15 kg weight loss. Neurologic exam showed gaze limitation and mild ataxia. Despite daily parenteral injection of thiamine 100 mg for 4 days, she died 5 days after the onset of neurologic symptoms. Combining the cases noted in the literature review with our 2 cases, the 7 gastric cancer cases and 2 colorectal cancer cases related to WE showed similar clinical characteristics; 1) a history of long-period malnutrition and weight loss, 2) relatively typical neurologic signs and symptoms and 3) specific magnetic resonance image findings. Except for 2 patients who had irreversible neurologic symptoms, the other 7 patients were improved with prompt thiamine treatment. CONCLUSION: It is important to consider WE in GI tract cancer patients with acute neurologic symptoms and who are in a state of malnutrition. Thiamine should be given as soon as possible when WE is suspected.
Ataxia
;
Colorectal Neoplasms
;
Diplopia
;
Dizziness
;
Female
;
Gastrointestinal Tract
;
Humans
;
Magnetic Resonance Spectroscopy
;
Malnutrition
;
Middle Aged
;
Neurologic Manifestations
;
Retrospective Studies
;
Stomach Neoplasms
;
Thiamine
;
Weight Loss
;
Wernicke Encephalopathy
10.A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy.
Gun Min KIM ; Hei Cheul JEUNG ; Dokyung KIM ; Joo Hoon KIM ; Sang Hyun YOON ; Eun Suk JUNG ; Sang Joon SHIN
Cancer Research and Treatment 2010;42(4):235-238
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m2 together with cisplatin at 70 mg/m2. After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.
Carcinoma, Hepatocellular
;
Cholangiocarcinoma
;
Cisplatin
;
Disease Progression
;
Doxorubicin
;
Fluorouracil
;
Follow-Up Studies
;
Humans
;
Incidence
;
Liver Neoplasms
;
Lung
;
Middle Aged
;
Neoplasm Metastasis
;
Niacinamide
;
Phenylurea Compounds
;
Thorax